Kevin specialises in contentious and non contentious intellectual property matters, focusing specifically on patent litigation, especially in the pharmaceuticals industry.
- Recent Work
- supervising patent expiry issues for a major scandinavian pharmaceutical company
- acting for GSK in patent proceedings relating to Advair/Seretide, the largest selling pharmaceutical product of the company
- acting for Sanofi Aventis in proceedings relating to Plavix, one of the largest selling drugs in the world
- acting for Lundbeck in relation to escitalopram, the largest selling SSRI in the world.
Kevin is recommended by "Chambers Guide to the Legal Profession" as being cited by peers as "the doyen of patent law". He is specifically recommend by Legal 500 for his "pre-eminent reputation for patent expertise". He is also specifically rated as a leader in his field by "The Legal 500", for Patent Litigation and in advising the Pharmaceutical and Biotechnology sector, and the "Global Counsel 3000". In 2009 he was listed for the third time as one of only eleven "Most Highly Regarded Individuals Global" in the field of patents by Who's Who Legal 2009.
He is a member of the Intellectual Property Solicitors Association, a member of the American Intellectual Property Law Association and a former member of the Nuffield Bioethics Council Working Party on Human Tissue. He is a former President and currently a Member of the Advisory Board of the European Patent Lawyers Association (EPLAW). He chaired the first three Venice conferences of European Patent Judges.
In August 2008 he was appointed by the Government to chair the Independent Review Panel for Borderline Products. In September 2009 he was also appointed by the Government to chair the Independent Review Panel for the Advertising of Medicinal Products.
He is the author of many articles and a frequent speaker in the UK, Europe and the US on intellectual property issues.
Kevin qualified as a solicitor in 1971 and became a partner in 1973.